Hjem › Multipel sklerose › Georgia
Multipel sklerose kliniske forsøg i Georgia
7 studier for Multipel sklerose søger deltagere på steder i Georgia.
Byer i Georgia
Officiel studietekst (engelsk)
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Atlanta Neuroscience Institute, Atlanta
RekruttererFase 4
Alder 18 til 65 · Alle køn · Opdateret 30. sep. 2026 · NCT07609719A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
- Local Institution - Site 102, Atlanta
RekruttererFase 2
Alder 18 til 70 · Alle køn · Opdateret 25. sep. 2026 · NCT07840326A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Atlanta
- TG Therapeutics Investigational Trial Site, Atlanta
- TG Therapeutics Investigational Trial Site, Savannah
- og 1 flere
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06433752RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Emory University, Atlanta
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 15. sep. 2026 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Joi Life Wellness Group LLC- Site Number : 8400192, Smyrna
RekruttererFase 3
Alder 18 til 60 · Alle køn · Opdateret 15. sep. 2026 · NCT07325292A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Joi Life Wellness Group LLC, Smyrna
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 29. jul. 2026 · NCT07225504Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
- Emory Univeristy, Atlanta
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 til 89 · Alle køn · Opdateret 16. jul. 2025 · NCT06495138Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.